Other Information.
−Removed: Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may
−Removed: represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.
−Removed: During the quarter ended September 30, 2023, no such plans or other arrangements were adopted or terminated.
+Added: Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule
+Added: 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.
+Added: During the quarter ended March 31, 2024, no such plans or other arrangements were adopted or terminated .
See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.
1 unchanged sentence
ADMA Biologics, Inc.
−Removed: November 8, 2023
−Removed: President and Chief Executive Officer
−Removed: November 8, 2023
−Removed: /s/ Brian Lenz
−Removed: Executive Vice President and Chief Financial Officer
+Added: President, Chief Executive Officer and Interim
+Added: Chief Financial Officer
EXHIBIT INDEX
Exhibit Number
−Removed: Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended September 30 2023, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Consolidated Balance Sheets as
−Removed: of September 30, 2023 (Unaudited) and December 31, 2022, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months and nine months ended September 30, 2023 and 2022, (iii) Condensed Consolidated Statements
−Removed: of Changes in Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2023 and 2022,
−Removed: and (v) Notes to (Unaudited) Condensed Consolidated Financial Statements.
+Added: Consulting Services Agreement, dated as of February 27, 2024, by and between ADMA Biologics, Inc.
+Added: and Brian Lenz (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on
+Added: February 28, 2024).
+Added: Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended March 31, 2024, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Condensed Consolidated Balance Sheets as of March
+Added: 31, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2024 and 2023, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity
+Added: (Unaudited) for the three months ended March 31, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2024 and 2023, and (v) Notes to (Unaudited) Condensed Consolidated
+Added: Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
−Removed: ** In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.
+Added: ** In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.